Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 3186328, 10 pages
https://doi.org/10.1155/2017/3186328
Review Article

HLA Association with Drug-Induced Adverse Reactions

1Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
2Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei, Taiwan
3Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
4Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
5Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
6College of Medicine, Chang Gung University, Taoyuan, Taiwan

Correspondence should be addressed to Wen-Hung Chung; moc.oohay@gnuhcgnuhnew

Received 1 September 2017; Accepted 24 October 2017; Published 23 November 2017

Academic Editor: Mahboobeh Mahdavinia

Copyright © 2017 Wen-Lang Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Cresswell, A. L. Ackerman, A. Giodini, D. R. Peaper, and P. A. Wearsch, “Mechanisms of MHC class I-restricted antigen processing and cross-presentation,” Immunological Reviews, vol. 207, no. 1, pp. 145–157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Shiina, K. Hosomichi, H. Inoko, and J. K. Kulski, “The HLA genomic loci map: expression, interaction, diversity and disease,” Journal of Human Genetics, vol. 54, no. 1, pp. 15–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Bray, C. K. Hurley, N. R. Kamani et al., “National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants,” Biology of Blood and Marrow Transplantation, vol. 14, no. 9, pp. 45–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. International drug monitoring, “The role of national centres. Report of a WHO meeting,” World Health Organization Technical Report Series, vol. 498, pp. 1–25, 1972. View at Google Scholar
  5. I. R. Edwards and J. K. Aronson, “Adverse drug reactions: definitions, diagnosis, and management,” The Lancet, vol. 356, no. 9237, pp. 1255–1259, 2000. View at Publisher · View at Google Scholar
  6. J. Lazarou, B. H. Pomeranz, and P. N. Corey, “Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies,” JAMA, vol. 279, no. 15, pp. 1200–1205, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Kvasz, I. E. Allen, M. J. Gordon et al., “Adverse drug reactions in hospitalized patients: a critique of a meta-analysis,” Medscape General Medicine, vol. 2, no. 2, article E3, 2000. View at Google Scholar
  8. A. Miguel, L. F. Azevedo, M. Araujo, and A. C. Pereira, “Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis,” Pharmacoepidemiology and Drug Safety, vol. 21, no. 11, pp. 1139–1154, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Falasca, C. Dello Russo, B. Mora et al., “Comparative analysis of real-time polymerase chain reaction methods to typing HLA-b57:01 in HIV-1-positive patients,” AIDS Research and Human Retroviruses, vol. 32, no. 7, pp. 654–657, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. W. H. Chung, C. W. Wang, and R. L. Dao, “Severe cutaneous adverse drug reactions,” The Journal of Dermatology, vol. 43, no. 7, pp. 758–766, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Ostapowicz, R. J. Fontana, F. V. Schiodt et al., “Results of a prospective study of acute liver failure at 17 tertiary care centers in the united states,” Annals of Internal Medicine, vol. 137, no. 12, pp. 947–954, 2002. View at Publisher · View at Google Scholar
  12. M. W. Russo, J. A. Galanko, R. Shrestha, M. W. Fried, and P. Watkins, “Liver transplantation for acute liver failure from drug induced liver injury in the united states,” Liver Transplantation, vol. 10, no. 8, pp. 1018–1023, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Bjornsson, P. Jerlstad, A. Bergqvist, and R. Olsson, “Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden,” Scandinavian Journal of Gastroenterology, vol. 40, no. 9, pp. 1095–1101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. F. J. de Abajo, D. Montero, M. Madurga, and L. A. Garcia Rodriguez, “Acute and clinically relevant drug-induced liver injury: a population based case-control study,” British Journal of Clinical Pharmacology, vol. 58, no. 1, pp. 71–80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Sgro, F. Clinard, K. Ouazir et al., “Incidence of drug-induced hepatic injuries: a French population-based study,” Hepatology, vol. 36, no. 2, pp. 451–455, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P. L. Chen, S. R. Shih, P. W. Wang et al., “Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study,” Nature Communications, vol. 6, p. 7633, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. W. J. Pichler, “Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept,” Current Opinion in Allergy and Clinical Immunology, vol. 2, no. 4, pp. 301–305, 2002. View at Publisher · View at Google Scholar
  18. S. Watkins and W. J. Pichler, “Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVΒ20-1, altering PHLA recognition,” PLoS One, vol. 8, no. 10, article e76211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. T. M. Ko, W. H. Chung, C. Y. Wei et al., “Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome,” The Journal of Allergy and Clinical Immunology, vol. 128, no. 6, pp. 1266–1276.e11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Y. Wei, W. H. Chung, H. W. Huang, Y. T. Chen, and S. I. Hung, “Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome,” The Journal of Allergy and Clinical Immunology, vol. 129, no. 6, pp. 1562–1569.e5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Hetherington, S. McGuirk, G. Powell et al., “Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir,” Clinical Therapeutics, vol. 23, no. 10, pp. 1603–1614, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Bossi, J. C. Roujeau, F. Bricaire, and E. Caumes, “Stevens-Johnson syndrome associated with abacavir therapy,” Clinical Infectious Diseases, vol. 35, no. 7, p. 902, 2002. View at Publisher · View at Google Scholar
  23. R. Pahk, M. C. Azu, B. R. Taira, and S. Sandoval, “Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus,” Clinical and Experimental Dermatology, vol. 34, no. 8, pp. e775–e777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Hetherington, A. R. Hughes, M. Mosteller et al., “Genetic variations in HLA-B region and hypersensitivity reactions to abacavir,” The Lancet, vol. 359, no. 9312, pp. 1121-1122, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Mallal, D. Nolan, C. Witt et al., “Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir,” The Lancet, vol. 359, no. 9308, pp. 727–732, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Saag, R. Balu, E. Phillips et al.A. Hughes, D. Sutherland‐Phillips, S. Mallal, M. Shaefer, and Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team, “High sensitivity of human leukocyte antigen-B5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients,” Clinical Infectious Diseases, vol. 46, no. 7, pp. 1111–1118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Martin, T. E. Klein, B. J. Dong et al., “Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing,” Clinical Pharmacology & Therapeutics, vol. 91, pp. 734–738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Y. Sun, C. C. Hung, P. H. Lin et al., “Incidence of abacavir hypersensitivity and its relationship with HLA-B5701 in HIV-infected patients in Taiwan,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 3, pp. 599–604, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Pirmohamed, D. A. Ostrov, and B. K. Park, “New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity,” The Journal of Allergy and Clinical Immunology, vol. 136, no. 2, pp. 236–244, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Yerly, Y. Pompeu, R. Schutte et al., “Structural elements recognized by abacavir-induced T cells,” International Journal of Molecular Sciences, vol. 18, no. 7, p. 1464, 2017. View at Publisher · View at Google Scholar
  31. V. L. M. Yip, A. Alfirevic, and M. Pirmohamed, “Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review,” Clinical Reviews in Allergy & Immunology, vol. 48, no. 2-3, pp. 165–175, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. A. G. Marson, A. M. Al-Kharusi, M. Alwaidh et al., “The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial,” The Lancet, vol. 369, no. 9566, pp. 1000–1015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. R. M. Post, T. A. Ketter, T. Uhde, and J. C. Ballenger, “Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice,” CNS Drugs, vol. 21, no. 1, pp. 47–71, 2007. View at Publisher · View at Google Scholar
  34. G. Cruccu, G. Gronseth, J. Alksne et al., “AAN-EFNS guidelines on trigeminal neuralgia management,” European Journal of Neurology, vol. 15, no. 10, pp. 1013–1028, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. W. H. Chung, S. I. Hung, H. S. Hong et al., “Medical genetics: a marker for Stevens-Johnson syndrome,” Nature, vol. 428, no. 6982, p. 486, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Tangamornsuksan, N. Chaiyakunapruk, R. Somkrua, M. Lohitnavy, and W. Tassaneeyakul, “Relationship between the HLA-B1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis,” JAMA Dermatology, vol. 149, no. 9, pp. 1025–1032, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Locharernkul, J. Loplumlert, C. Limotai et al., “Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B1502 allele in Thai population,” Epilepsia, vol. 49, pp. 2087–2091, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Y. Mehta, L. M. Prajapati, B. Mittal et al., “Association of HLA-B1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians,” Indian Journal of Dermatology, Venereology and Leprology, vol. 75, no. 6, pp. 579–582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Chen, J. J. Lin, C. S. Lu et al., “Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan,” The New England Journal of Medicine, vol. 364, no. 12, pp. 1126–1133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. B. Ferrell Jr. and H. L. McLeod, “Carbamazepine, HLA-B1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations,” Pharmacogenomics, vol. 9, no. 10, pp. 1543–1546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. H. Kim, K. W. Lee, W. J. Song et al.K. U. Min, Y. S. Chang, and Adverse Drug Reaction Research Group in Korea, “Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans,” Epilepsy Research, vol. 97, no. 1-2, pp. 190–197, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Kano, K. Hirahara, Y. Asano, and T. Shiohara, “HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions,” Acta Dermato-Venereologica, vol. 88, no. 6, pp. 616–618, 2008. View at Google Scholar
  43. R. Aggarwal, M. Sharma, M. Modi, V. K. Garg, and M. Salaria, “HLA-B 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population,” Human Immunology, vol. 75, no. 11, pp. 1120–1122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. C. C. Chang, C. L. Too, S. Murad, and S. H. Hussein, “Association of HLA-B1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population,” International Journal of Dermatology, vol. 50, no. 2, pp. 221–224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. X. J. He, L. Y. Jian, X. L. He et al., “Association between the HLA-B15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in HAN individuals of Northeastern China,” Pharmacological Reports, vol. 65, no. 5, pp. 1256–1262, 2013. View at Publisher · View at Google Scholar
  46. A. Alfirevic, A. L. Jorgensen, P. R. Williamson, D. W. Chadwick, B. K. Park, and M. Pirmohamed, “HLA-B locus in Caucasian patients with carbamazepine hypersensitivity,” Pharmacogenomics, vol. 7, no. 6, pp. 813–818, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Kaniwa, Y. Saito, M. Aihara et al., “HLA-B1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients,” Epilepsia, vol. 51, no. 12, pp. 2461–2465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. McCormack, A. Alfirevic, S. Bourgeois et al., “HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans,” The New England Journal of Medicine, vol. 364, no. 12, pp. 1134–1143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Genin, D. P. Chen, S. I. Hung et al., “HLA-A31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis,” The Pharmacogenomics Journal, vol. 14, no. 3, pp. 281–288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Ozeki, T. Mushiroda, A. Yowang et al., “Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population,” Human Molecular Genetics, vol. 20, no. 5, pp. 1034–1041, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. C. B. Chen, Y. H. Hsiao, T. Wu et al., “Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians,” Neurology, vol. 88, no. 1, pp. 78–86, 2017. View at Publisher · View at Google Scholar
  52. C. Y. Yang, C. H. Chen, S. T. Deng et al., “Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan,” JAMA Internal Medicine, vol. 175, no. 9, pp. 1550–1557, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. S. I. Hung, W. H. Chung, L. B. Liou et al., “HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 11, pp. 4134–4139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. H. R. Kang, Y. K. Jee, Y. S. Kim et al., “Positive and negative associations of HLA class I alleles with allopurinol-induced scars in Koreans,” Pharmacogenetics and Genomics, vol. 21, no. 5, pp. 303–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Kaniwa, Y. Saito, M. Aihara et al., “HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis,” Pharmacogenomics, vol. 9, no. 11, pp. 1617–1622, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. M. H. Lee, S. L. Stocker, J. Anderson et al., “Initiating allopurinol therapy: do we need to know the patient’s human leucocyte antigen status?” Internal Medicine Journal, vol. 42, no. 4, pp. 411–416, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Lonjou, N. Borot, P. Sekula et al., “A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs,” Pharmacogenetics and Genomics, vol. 18, no. 2, pp. 99–107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Y. Ng, Y. T. Yeh, C. W. Wang et al., “Impact of the HLA-B58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions,” The Journal of Investigative Dermatology, vol. 136, no. 7, pp. 1373–1381, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. W. Tassaneeyakul, T. Jantararoungtong, P. Chen et al., “Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population,” Pharmacogenetics and Genomics, vol. 19, no. 9, pp. 704–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. F. R. Zhang, H. Liu, A. Irwanto et al., “HLA-B13:01 and the dapsone hypersensitivity syndrome,” The New England Journal of Medicine, vol. 369, no. 17, pp. 1620–1628, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. M. L. Hautekeete, Y. Horsmans, C. Van Waeyenberge et al., “HLA association of amoxicillin-clavulanate–induced hepatitis,” Gastroenterology, vol. 117, no. 5, pp. 1181–1186, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. P. T. Donaldson, A. K. Daly, J. Henderson et al., “Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury,” Journal of Hepatology, vol. 53, no. 6, pp. 1049–1053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. J. O'Donohue, K. A. Oien, P. Donaldson et al., “Co-amoxiclav jaundice: clinical and histological features and HLA class II association,” Gut, vol. 47, no. 5, pp. 717–720, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. M. I. Lucena, M. Molokhia, Y. Shen et al., “Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles,” Gastroenterology, vol. 141, no. 1, pp. 338–347, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. A. K. Daly, P. T. Donaldson, P. Bhatnagar et al., “HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin,” Nature Genetics, vol. 41, no. 7, pp. 816–819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Dunckley, “HLA typing by SSO and SSP methods,” Methods in Molecular Biology, vol. 882, pp. 9–25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. B. P. Wordsworth, C. E. Allsopp, R. P. Young, and J. I. Bell, “HLA-DR typing using DNA amplification by the polymerase chain reaction and sequential hybridization to sequence-specific oligonucleotide probes,” Immunogenetics, vol. 32, no. 6, pp. 413–418, 1990. View at Publisher · View at Google Scholar · View at Scopus
  68. A. M. Martin, D. Nolan, and S. Mallal, “HLA-B5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing,” Tissue Antigens, vol. 65, no. 6, pp. 571–574, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. O. Olerup and H. Zetterquist, “HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation,” Tissue Antigens, vol. 39, no. 5, pp. 225–235, 1992. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Stocchi, R. Cascella, S. Zampatti, A. Pirazzoli, G. Novelli, and E. Giardina, “The pharmacogenomic HLA biomarker associated to adverse abacavir reactions: comparative analysis of different genotyping methods,” Current Genomics, vol. 13, no. 4, pp. 314–320, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Dello Russo, L. Lisi, A. Lofaro et al., “Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B57:01 detection by real-time PCR,” Pharmacogenomics, vol. 12, no. 4, pp. 567–576, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Hammond, C. Mamotte, D. Nolan, and S. Mallal, “HLA-B5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay,” Tissue Antigens, vol. 70, no. 1, pp. 58–61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. H. S. Jung, G. J. Tsongalis, and J. A. Lefferts, “Development of HLA-B57:01 genotyping real-time PCR with optimized hydrolysis probe design,” The Journal of Molecular Diagnostics, vol. 19, no. 5, pp. 742–754, 2017. View at Publisher · View at Google Scholar
  74. L. Kostenko, L. Kjer-Nielsen, I. Nicholson et al., “Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity,” Tissue Antigens, vol. 78, no. 1, pp. 11–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Giorgini, C. Martinelli, L. Tognetti et al., “Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients,” Dermatologic Therapy, vol. 24, no. 6, pp. 591–594, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. Y.-T. Lin, Y.-C. Chang, R. C.-Y. Hui et al., “A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions,” Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 3, pp. 356–364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. F. F. Gonzalez-Galarza, L. Y. C. Takeshita, E. J. M. Santos et al., “Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations,” Nucleic Acids Research, vol. 43, no. D1, pp. D784–D788, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. G. S. Ghattaoraya, Y. Dundar, F. F. González-Galarza et al., “A web resource for mining HLA associations with adverse drug reactions: HLA-ADR,” Database, vol. 2016, article baw069, 2016. View at Publisher · View at Google Scholar
  79. S. Crovella, L. Biller, S. Santos et al., “Frequency of HLA B5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil,” Clinics, vol. 66, no. 8, pp. 1485–1488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Chakravarty, S. Sharma, A. Johri, A. Chourasia, and S. Sundar, “Clinical abacavir hypersensitivity reaction among children in India,” Indian Journal of Pediatrics, vol. 83, no. 8, pp. 855–858, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Baniasadi, S. B. Shokouhi, P. Tabarsi et al., “Prevalence of HLA-B5701 and its relationship with abacavir hypersensitivity reaction in Iranian HIV-infected patients,” Tanaffos, vol. 15, no. 1, pp. 48–52, 2016. View at Google Scholar
  82. S. I. Hung, W. H. Chung, S. H. Jee et al., “Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions,” Pharmacogenetics and Genomics, vol. 16, no. 4, pp. 297–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. C. B. Man, P. Kwan, L. Baum et al., “Association between HLA-B1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese,” Epilepsia, vol. 48, no. 5, pp. 1015–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. S. H. Kim, M. Kim, K. W. Lee et al., “HLA-B5901 is strongly associated with methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis,” Pharmacogenomics, vol. 11, no. 6, pp. 879–884, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. T. M. Ko, C. Y. Tsai, S. Y. Chen et al., “Use of HLA-B58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study,” BMJ, vol. 351, article h4848, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. M. McCormack, T. J. Urban, K. V. Shianna et al., “Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions,” Pharmacogenomics, vol. 13, no. 4, pp. 399–405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. A. M. Martin, D. Nolan, I. James et al., “Predisposition to nevirapine hypersensitivity associated with HLA-DRB10101 and abrogated by low CD4 T-cell counts,” AIDS, vol. 19, no. 1, pp. 97–99, 2005. View at Publisher · View at Google Scholar
  88. R. Littera, C. Carcassi, A. Masala et al., “HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients,” AIDS, vol. 20, no. 12, pp. 1621–1626, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Arnaldo, R. E. Thompson, M. Q. Lopes, P. N. Suffys, and A. R. Santos, “Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population,” The Malaysian Journal of Medical Sciences, vol. 20, no. 4, pp. 13–23, 2013. View at Google Scholar
  90. J. B. Singer, S. Lewitzky, E. Leroy et al., “A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury,” Nature Genetics, vol. 42, no. 8, pp. 711–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Hirata, H. Takagi, M. Yamamoto et al., “Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study,” The Pharmacogenomics Journal, vol. 8, no. 1, pp. 29–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Ng, C. K. Hurley, L. A. Baxter-Lowe et al., “Large-scale oligonucleotide typing for HLA-DRB1/3/4 and HLA-DQB1 is highly accurate, specific, and reliable,” Tissue Antigens, vol. 42, no. 5, pp. 473–479, 1993. View at Publisher · View at Google Scholar · View at Scopus
  93. W. De Spiegelaere, J. Philippe, K. Vervisch et al., “Comparison of methods for in-house screening of HLA-B57:01 to prevent abacavir hypersensitivity in HIV-1 care,” PLoS One, vol. 10, no. 4, article e0123525, 2015. View at Publisher · View at Google Scholar · View at Scopus